A 3-day-old term neonate born to an O-positive mother presents with clinical jaundice. The mother is O-negative and unsensitized (indirect Coombs test negative at delivery). The infant's total serum bilirubin is 14 mg/dL. Which investigation is most appropriate to confirm hemolytic disease and guide management?

## Investigation of Choice for Suspected Hemolytic Jaundice ### Clinical Context This neonate has risk factors for hemolytic disease: - ABO incompatibility (O-negative mother, O-positive infant) - Early-onset jaundice (day 3) - Elevated bilirubin requiring intervention ### Why Direct Antiglobulin Test (DAT) is Correct **Key Point:** The DAT detects **IgG antibodies bound directly to the surface of fetal/neonatal red blood cells**, confirming in-vivo hemolysis. **High-Yield:** DAT is the **gold standard confirmatory test** for hemolytic disease of the newborn (HDN). A positive DAT in the presence of clinical jaundice and elevated bilirubin establishes hemolysis as the etiology. **Clinical Pearl:** Even though the mother's indirect Coombs was negative (unsensitized), ABO incompatibility can still cause hemolysis because naturally occurring maternal IgG anti-A and anti-B antibodies cross the placenta. The infant's DAT will be positive. ### Interpretation Algorithm ```mermaid flowchart TD A[Neonatal jaundice + risk factors]:::outcome --> B{DAT positive?}:::decision B -->|Yes| C[Hemolytic disease confirmed]:::outcome C --> D[Check reticulocyte count<br/>and LDH/indirect bili]:::action B -->|No| E[Non-hemolytic jaundice<br/>e.g., physiologic, breast milk]:::outcome E --> F[Assess phototherapy<br/>threshold by age]:::action ``` ### Comparison of Tests in Hemolytic Jaundice | Investigation | Specificity | Timing | Role | |---|---|---|---| | **DAT (Direct Coombs)** | Confirms hemolysis | Stat | Gold standard; detects RBC-bound antibodies | | Indirect Coombs (maternal) | Screens for alloimmunization | Antenatal/delivery | Negative does NOT exclude ABO incompatibility | | Reticulocyte count | Reflects bone marrow response | Day 3–5 | Elevated in hemolysis; supports diagnosis | | Transcutaneous bilirubinometry | Non-invasive bilirubin estimate | Bedside | Screening tool; NOT diagnostic for hemolysis | | Peripheral smear | Morphology | Day 3+ | Shows spherocytes, polychromasia in hemolysis | **Key Point:** A **positive DAT + elevated bilirubin + clinical jaundice = hemolytic disease** until proven otherwise. [cite:Park 26e Ch 11]